Abstract. Recent studies have identified several microRNAs (miRNAs/miRs) that are dysregulated in clear cell renal cell carcinoma
Introduction
Renal cell carcinoma (RCC), originates from cells in the renal cortex and is the most common type of kidney cancer in adults worldwide, with ~270,000 new cases and ~116,000 RCC-associated mortalities each year (1, 2) . RCC is divided into three major subtypes, including clear cell RCC (ccRCC), papillary RCC and chromophobe RCC (3) . ccRCC is the most common and aggressive of the three subtypes, and accounts for ~80-90% of all RCC cases (4) . Despite recent advances in cancer treatment, the long-term prognosis of patients with advanced ccRCC is poor, with a median survival rate of 1.5 years (5) . Metastasis, lymph node recurrence and cancer recurrence are the main factors associated with poor prognosis in patients with ccRCC (6) . In ~33% of cases, patients with ccRCC are diagnosed with local or distant metastases due to its variable clinical presentation (7) . In addition, there is a 40% recurrence rate in patients with ccRCC following surgery (8, 9) . Therefore, identifying novel therapeutic targets may improve the survival outcome and treatment response of patients with advanced ccRCC.
MicroRNAs (miRNAs/miRs) are a group of endogenous, short, non-coding RNAs ~18-23 nucleotides in length (10) . MiRNAs regulate multiple biological and pathological processes, including carcinogenesis and cancer progression (11) . miRNAs promote mRNA degradation or inhibition of mRNA translation by binding to the complementary binding sites in the 3'-untranslated region (3'-UTR) of target genes (12) . Several studies have demonstrated that miRNA deregulation is common in almost all types of human cancer (13) (14) (15) . Previous studies have identified several deregulated miRNAs associated with ccRCC, whereby oncogenic MicroRNA-508 is downregulated in clear cell renal cell carcinoma and targets ZEB1 to suppress cell proliferation and invasion miRNAs are upregulated and tumor suppressor miRNAs are downregulated (16) (17) (18) . Aberrantly expressed miRNAs are involved in the pathogenesis of ccRCC and are involved in numerous processes, including cell proliferation, cell cycle progression, apoptosis, metastasis, epithelial-to-mesenchymal transition and chemoresistance (19) (20) (21) . miRNAs may therefore be used as potential biomarkers to improve early diagnosis and prognosis of patients with ccRCC. Previous studies have demonstrated that miR-508 is abnormally expressed in several types of human cancer, including ovarian (22) and colorectal cancer (23) and esophageal squamous cell carcinoma (24) . An additional study revealed that miR-508 is downregulated in RCC and may be involved in regulating cell migration and apoptosis (25) . Therefore, the aim of the current study was to investigate the expression pattern and biological function of miR-508 in the pathogenesis of ccRCC, as well as investigate the underlying molecular mechanisms of miR-508 in the development and progression of ccRCC.
Materials and methods

Human tissue samples.
A total of 21 ccRCC tissue and paired adjacent normal tissue samples were collected from patients that had undergone surgical resection at the Lanzhou University Second Hospital (Lanzhou, China) between May 2015 and February 2017. None of the patients had received radiotherapy or chemotherapy treatment prior to surgical resection. All tissue samples were taken immediately after tumor resection, frozen in liquid nitrogen and stored at -80˚C. The current study was approved by the Ethics Committee of Lanzhou University Second Hospital and written informed consent was obtained from each patient. The clinicopathological features of patients with ccRCC are summarized in Table I .
Cell culture. The normal human renal cell line HK-2, the papillary RCC cell lines Caki-2 and ACHN, and two ccRCC cell lines 786-O and A498 were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin (all purchased from Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and maintained at 37˚C in a 5% CO 2 -humidified incubator.
Cell transfection. miR-508 mimics, negative control miRNA mimics (miR-NC), small interfering RNA (siRNA) targeting the expression of zinc finger E-box-binding homeobox 1 (ZEB1 siRNA) and negative control siRNA (NC siRNA) were synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). The miR-508 mimics sequence was 5'-UGA UUG UAG CCU UUU GGA GUA GA-3' and the miR-NC sequence was 5'-UUC UCC GAA CGU GUC ACG UTT-3'. The ZEB1 siRNA sequence was 5'-GUC GCU ACA AAC AGU UGU ATT-3' and the NC siRNA sequence was 5'-UUC UCC GAA CGU GUC ACG UTT-3'. The ZEB1-overexpression plasmid, pcDNA3.1-ZEB1 and empty pcDNA3.1 plasmid were synthesized by GeneCopoeia, Inc., (Rockville, MD, USA). Cells were seeded into six-well plates at a density of 6x10 5 cells/well. miR-508 mimics (100 pmol), miR-NC (100 pmol), ZEB1 siRNA (100 pmol), NC siRNA (100 pmol), pcDNA3.1-ZEB1 (4 µg) or empty pcDNA3.1 plasmids (4 µg) were transfected into cells using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. At 6 h following incubation at 37˚C in a 5% CO 2 -humidified incubator, the medium was replaced with complete culture medium. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and cell proliferation assay was performed at 24 h post-transfection. Transwell invasion assay was performed in transfected cells following 48 h of incubation. Following 72 h culture, western blot analysis was utilized for the measurement of protein expression.
RT-qPCR. Total RNA was extracted from cells using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to on the manufacturer's protocol. To examine the expression of miR-508, total miRNA was first reverse transcribed into cDNA using the TaqMan ® MicroRNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). The temperature protocol for reverse transcription was as follows: 16˚C for 30 min, 42˚C for 30 min and 85˚C for 5 min. qPCR was subsequently performed using the TaqMan MicroRNA Assay kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). The temperature protocol for qPCR were as follows: 50˚C for 2 min, 95˚C for 10 min; 40 cycles of denaturation at 95˚C for 15 sec; and annealing/extension at 60˚C for 60 sec. To analyze ZEB1 mRNA expression levels, total RNA was first reverse transcribed into cDNA using the PrimeScript RT Reagent kit (Takara Biotechnology, Co., Ltd., Dalian, China). The temperature protocol for reverse transcription was as follows: 37˚C for 15 min and 85˚C for 5 sec. qPCR was subsequently performed using the SYBR Premix Ex Taq™ kit (Takara Biotechnology, Co., Ltd.). The temperature protocol for qPCR was as follows: 5 min at 95˚C, followed by 40 cycles of 95˚C for 30 sec and 65˚C for 45 sec. ZEB1 and miR-508 expression was quantified using the 2 -ΔΔCq method and normalized to the internal reference gene GAPDH or U6 small nuclear RNA, respectively (26) . The primer sequences used were as follows: miR-508 forward, 5'-TTC AAG AGA CAT GAG TGA C-3' and reverse, 5'-TCT CTT GAA CAT GAG TGA CG-3'; U6 forward, 5'-TGC GGG TGC TCG CTT CGG CAG C-3' and reverse, 5'-CCA GTG CAG GGT CCG AGG T-3'; ZEB1 forward, 5'-AAG TGG CGG TAG ATG GTA-3' and reverse, 5'-TTG TAG CGA CTG GAT TTT-3'; and GAPDH forward, 5'-AAC GGA TTT GGT CGT ATT G-3' and reverse, 5'-GGA AGA TGG TGA TGG GAT T-3'.
Cell proliferation assay. The proliferative ability of ccRCC cells was analyzed using the cell counting kit-8 assay (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan). Briefly, transfected cells were collected and seeded into 96-well plates at a density of 3x10 3 cells/well and cultured for 0, 24, 48 and 72 h at 37˚C. Following incubation, 10 µl CCK-8 reagent was then added to each well and the cells were incubated for an additional 2 h at 37˚C. Cell proliferation was determined by measuring the absorbance at a wavelength of 450 nm using the SpectraMax Microplate ® Spectrophotometer (Molecular Devices LLC, Sunnyvale, CA, USA).
Transwell invasion assay. ccRCC cell invasion was examined using an in vitro Transwell invasion chamber assay using Transwell™ polycarbonate membrane inserts for 24-well plates containing 8-µm pores (Corning Inc., Corning, NY, USA) precoated with Matrigel ® (BD Biosciences, San Jose, CA, USA). Following transfection, 5x10 4 cells in serum-free DMEM were added to the upper chamber of the Transwell insert. In the lower chamber, 600 µl DMEM supplemented with 10% FBS was used as a chemo-attractant, and the plates were incubated at 37˚C in a 5% CO 2 -humidified incubator for 24 h. Non-invasive cells remaining on the polycarbonate membrane were carefully removed and invaded cells were fixed with 100% methanol at room temperature for 30 min and stained with 0.1% crystal violet at room temperature for 30 min. The invasive capacity of ccRCC cells was quantified by counting the number of invaded cells in five randomly selected visual fields/chamber under an inverted light microscope (x200 magnification).
Bioinformatics analysis and dual-luciferase reporter assay. TargetScan (http://www.targetscan.org) and miRDB (http://mirdb.org) databases were used to identify putative targets of miR-508. ZEB1 was predicted as a potential target gene of miR-508. The wild-type (wt) and mutant (mut) fragments of the ZEB1 3'-UTR (synthesized by Shanghai GenePharma Co., Ltd.) were amplified by PCR and cloned into the firefly luciferase-expressing pmirGLO luciferase reporter plasmid (Promega Corporation, Madison, WI, USA). Cells were seeded into 24-well plates and incubated at 37˚C in a CO 2 -humidified incubator for 24 h prior to transfection. Cells were subsequently co-transfected with miR-508 mimics or miR-NC and wt or mut 3'-UTR ZEB1 luciferase reporter plasmids using Lipofectamine ® 2000. Following incubation for 48 h, luciferase activities were detected using the Dual-Luciferase Reporter assay system (Promega Corporation), according to the manufacturer's protocol. Firefly luciferase activity was normalized to that of Renilla luciferase activity.
Western blot analysis. Total protein was extracted from tissues or cells using ice-cold radioimmunoprecipitation assay buffer (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with proteinase inhibitor cocktail (Roche Applied Science, Penzberg, Germany). Total protein was quantified using a bicinchoninic acid assay kit (Pierce; Thermo Fisher Scientific, Inc.) and equal quantities of protein (30 µg/lane) were separated via SDS-PAGE on a 10% gel. The separated proteins were transferred onto polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA) and blocked for 1 h at room temperature with 5% skimmed milk in Tris-buffered saline containing 0.05% Tween-20. The membranes were incubated with the following primary antibodies: Mouse anti-human monoclonal ZEB1 (dilution, 1:1,000; cat. no. sc-81428) or mouse anti-human monoclonal GAPDH (dilution, 1:1,000; cat. no. sc-47724; both Santa Cruz Biotechnology, Inc., Dallas, TX, USA) overnight at 4˚C. Following primary incubation, the membranes were subsequently incubated with goat-anti mouse horseradish peroxidase-labeled secondary antibody (dilution, 1:5,000; cat. no. sc-516102; Santa Cruz Biotechnology, Inc.) at room temperature for 2 h. Protein bands were visualized using enhanced chemiluminescence detection reagent (EMD Millipore), according to the manufacturer's protocol. Protein expression was quantified by normalizing target protein expression to the GAPDH loading control. Quantity One software version 4.62 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used for densitometry analysis.
Statistical analysis. The results are presented as the mean ± standard deviation from at least three independent experiments. All statistical analyses were performed using SPSS software (version 19.0; IBM Corp., Armonk, NY, USA). The statistical significance of differences between two groups was analyzed using a two-tailed, paired Student's t-test. One-way analysis of variance followed by the Student-Newman-Keuls post hoc test was used to analyze differences among multiple groups. The association between miR-508 and ZEB1 mRNA expression in ccRCC tissue samples was determined using Spearman's correlation analysis. P<0.05 was considered to indicate a statistically significant difference.
Results
miR-508 expression is downregulated in ccRCC tissue samples and cell lines.
To investigate the expression pattern of miR-508 in ccRCC, the expression levels of miR-508 in ccRCC tissue samples and adjacent normal tissue samples Taken together, these results suggest that miR-508 may serve a tumor-suppressive role in the development of ccRCC.
ZEB1 is a direct target gene of miR-508 in ccRCC cells.
It is well established that miRNAs directly target mRNAs of target genes, thereby exerting their role as post-transcriptional regulators (12) . To further investigate the mechanisms underlying the tumor suppressive role of miR-508 in ccRCC in the present study, putative targets of miR-508 were examined by bioinformatics analysis. TargetScan and miRDB databases identified ZEB1, which contains a 3'-UTR sequence complementary to the seed sequence of miR-508 (Fig. 3A) . Therefore, ZEB1 was selected for verification using a dual-luciferase reporter assay. This assay was used to confirm whether miR-508 binds directly to the partially complimentary sequence within the 3'-UTR of ZEB1 in ccRCC cells. The results demonstrated that miR-508 overexpression significantly decreased the luciferase activity of the reporter plasmid containing the wt miR-508 binding site, whereas co-transfection with the mut miR-508 binding site plasmid demonstrated no effect on luciferase activity (P<0.05; Fig. 3B ).
To further understand the association between miR-508 and ZEB1 in ccRCC, the expression of ZEB1 was analyzed using RT-qPCR in ccRCC and normal adjacent tissue samples from patients with ccRCC. The mRNA levels of ZEB1 were significantly increased in ccRCC tissue samples when compared with adjacent normal tissue samples (P<0.05; Fig. 3C ). In addiIn addition, Spearman's correlation analysis indicated a statistically significant negative correlation between miR-508 and ZEB1 mRNA expression levels in ccRCC tissue samples (r=-0.5436, P= 0.0019; Fig. 3D ). To investigate whether ZEB1 expression was regulated by miR-508 in ccRCC cells, ZEB1 expression levels were determined by RT-qPCR in 786-O and A498 cells transfected with miR-508 mimics or miR-NC. The mRNA and protein expression levels of ZEB1 significantly decreased following miR-508 overexpression compared with the negative controls (P<0.05; Fig. 3E and F) . These results suggest that ZEB1 may be a direct target of miR-508 in ccRCC cells.
Inhibition of ZEB1 suppresses ccRCC cell proliferation and invasion.
To examine the biological role of ZEB1 in ccRCC, 786-O and A498 cells were transfected with ZEB1 siRNA or NC siRNA. Endogenous ZEB1 protein expression was significantly decreased in ccRCC cells following transfection with ZEB1 siRNA when compared with NC siRNA (P<0.05; Fig. 4A ). CCK-8 and in vitro Transwell invasion assays were used to examine the effect of ZEB1 knockdown on ccRCC cell proliferation and invasion, respectively. The results demonstrated that ZEB1 knockdown significantly inhibited the proliferative and invasive ability of 786-O and A498 cells when compared with the negative controls (P<0.05; Fig. 4B and C) . Taken together, these results demonstrated that ZEB1 knockdown exerts a functional role similar to that of miR-508 overexpression in ccRCC cells, which suggests that ZEB1 may be a functional target of miR-508 in ccRCC. 
Restoration of ZEB1 expression reverses the suppressive effects of miR-508 on the malignant phenotype of ccRCC cells.
As ZEB1 was identified as a direct target of miR-508 in ccRCC, rescue assays were performed to determine whether ZEB1 knockdown was responsible for the miR-508-induced inhibitory effects on ccRCC cell proliferation and invasion. ccRCC cell lines 786-O and A498 were co-transfected with miR-508 mimics and pcDNA3.1 or pcDNA3.1-ZEB1. Western blot analysis confirmed that the relative protein expression levels of ZEB1 were significantly increased in ccRCC cells following co-transfection with miR-508 mimics and pcDNA3.1-ZEB1 compared with miR-508 mimics and the pcDNA3.1 negative control (P<0.05; Fig. 5A) . Furthermore, functional analysis demonstrated that restoration of ZEB1 expression significantly reversed the inhibitory effects of miR-508 on ccRCC cell proliferation and invasion (P<0.05; Fig. 5B and C) . These results suggest that miR-508 may serve a tumor suppressive role in ccRCC and that the inhibitory effects of this miRNA may be, in part, mediated by regulating ZEB1 expression.
Discussion
A number of recent studies have identified a variety of deregulated miRNAs in ccRCC, including miR-224 (27), miR-502 (28), miR-543 (18) and miR-645 (29) . miRNAs are involved in several biological and pathological processes, including ccRCC occurrence and development (30) (31) (32) . Previous studies have also identified several deregulated miRNAs in ccRCC, whereby oncogenic miRNAs are upregulated and tumor suppressor miRNAs are downregulated (17, 33) . Therefore, understanding the expression pattern and biological function of miRNAs in ccRCC, as well as the underlying mechanisms of miRNAs in the development and progression of ccRCC, may be useful for the identification of novel therapeutic targets in the treatment of patients with ccRCC. In the current study, miR-508 expression in ccRCC tissue samples and cell lines was examined and the regulatory effects of miR-508 in the development of ccRCC in vitro were examined. Furthermore, the underlying molecular mechaFurthermore, the underlying molecular mechanisms of miR-508 in ccRCC cells were investigated. The current study identified miR-508 as a putative novel biomarker in the diagnosis of ccRCC, as well as a potentially novel and efficient therapeutic target for the treatment of patients with ccRCC.
Previous studies have demonstrated that miR-508 expression is downregulated in ovarian cancer (22) and colorectal cancer (23) compared with normal tissues of the same type. By contrast, miR-508 was observed to be upregulated in esophageal squamous cell carcinoma compared with normal esophageal tissues (24) . Patients with esophageal squamous cell carcinoma expressing high levels of miR-508 exhibited worse survival rates when compared with patients with low miR-508 expression (24) . However, the expression status of miR-508 in ccRCC requires further investigation. In the present study, miR-508 expression was significantly decreased in ccRCC tissue samples and cell lines when compared with adjacent normal tissue samples and the normal human renal cell line HK-2, respectively. These conflicting results suggest that miR-508 may exert tissue-specific expression patterns, and miR-508 may therefore present a potential diagnostic biomarker for patients with these types of cancer.
Previous studies have demonstrated that aberrant miR-508 expression may contribute to the development and progression of several types of human cancer (22) (23) (24) . Upregulation of miR-508 suppressed cell proliferation, metastasis and epithelial-to-mesenchymal transition in ovarian cancer via the mitogen-activated protein kinase 1 signaling pathway (22) . In addition, Yan et al (23) reported that ectopic expression of miR-508 in colorectal cancer cells attenuated epithelial-to-mesenchymal transition, stemness and metastasis in vitro and in vivo. By contrast, miR-508 exerts an oncogenic role in esophageal squamous cell carcinoma by promoting tumorigenicity both in vivo and in vitro (24) . These studies suggest that the role of miR-508 in cancer development and progression may be tissue specific. miR-508 may function as tumour suppressor or promoter in different types of human cancer, depending on the characteristics of corresponding target genes (34) . However, the potential role of miR-508 in ccRCC remains unknown. In the current study, functional experiments indicated that miR-508 overexpression inhibited the proliferation and invasion of ccRCC cells. These findings suggest that miR-508 may serve as a potential therapeutic target in the treatment of patients with ccRCC. miRNAs regulate several biological and pathological processes, including tumorigenesis, by binding to specific sites within the 3'-UTR of target mRNA sequences to inhibit their translation and expression (12) . In the current study, the under- (12) . In the current study, the underlying mechanism of miR-508 in ccRCC cells was investigated. Bioinformatics analysis identified ZEB1, which contains a 3'-UTR sequence complementary to the seed sequence of miR-508. Therefore, ZEB1 was considered a potential target gene of miR-508 in the present study. A dual-luciferase reporter assay was used to confirm a direct interaction between the 3'-UTR of ZEB1 and miR-508 in ccRCC cells. RT-qPCR and western blot analyses revealed that the mRNA and protein expression levels of ZEB1 were negatively regulated by miR-508 in ccRCC cells. In addition, the current study demonstrated that ZEB1 expression was significantly increased in ccRCC tissue samples, and ZEB1 expression was inversely correlated with miR-508 expression in these tissue samples. Finally, restoration of ZEB1 expression reversed the inhibitory effect of miR-508 on the malignant phenotype of ccRCC cells. Taken together, these results suggest that ZEB1 is a direct and functional downstream target of miR-508 in ccRCC cells.
ZEB1, located on the short arm of human chromosome 10, is a member of the ZEB family of transcription factors (35) . Previous studies have demonstrated that ZEB1 is upregulated in several types of cancer, including lung (36), gastric (37), colorectal (38) and endometrial cancers (39) . Overexpression of ZEB1 has also been identified in ccRCC, and ZEB1 overexpression was significantly correlated with tumor grade, tumor, node and metastasis stage, lymph node metastasis and distant metastases (40) . In addition, patients with ccRCC expressing high ZEB1 expression levels exhibited worse overall and progression-free survival when compared with low ZEB1 expression (40) . Furthermore, ZEB1 was demonstrated to be involved in several biological processes in ccRCC development and progression (41) . The current study demonstrated that miR-508 directly targets ZEB1 and suppresses ccRCC cell proliferation and invasion. The miR-508-ZEB1 axis may therefore be a novel and efficient therapeutic target, which could be used to inhibit the rapid growth and metastasis of ccRCC.
In conclusion, to the best of the authors' knowledge, the current study is the first to demonstrate that miR-508 is downregulated in ccRCC and that miR-508 may inhibit the development of ccRCC by directly targeting ZEB1. The miR-508-ZEB1 axis may present a potential therapeutic target in the treatment of patients with ccRCC patients. However, the current study has several limitations that will need to be addressed in future studies. The effect of miR-508 in cell apoptosis, in vivo tumor growth, angiogenesis, energy metabolism and drug resistance were not examined. Due to the relatively small sample size, the correlation between clinicopathological features and miR-508 expression in ccRCC tissue samples was also not examined. Furthermore, future studies will be required to validate miR-508 as a potential biomarker in the early diagnosis and prognosis of patients with ccRCC.
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